The first two authors contributed equally to this work.
Clinical utility of anti-glycan antibodies in pediatric crohn's disease in comparison with an adult cohort
Version of Record online: 6 DEC 2011
Copyright © 2011 Crohn's & Colitis Foundation of America, Inc.
Inflammatory Bowel Diseases
Volume 18, Issue 7, pages 1221–1231, July 2012
How to Cite
Rieder, F., Hahn, P., Finsterhoelzl, L., Schleder, S., Wolf, A., Dirmeier, A., Lopez, R., Shen, B., Rogler, G., Klebl, F. and Lang, T. (2012), Clinical utility of anti-glycan antibodies in pediatric crohn's disease in comparison with an adult cohort. Inflamm Bowel Dis, 18: 1221–1231. doi: 10.1002/ibd.21854
- Issue online: 11 JUN 2012
- Version of Record online: 6 DEC 2011
- Manuscript Accepted: 15 JUL 2011
- Manuscript Received: 6 JUL 2011
- the German Ministry of Education and Research (BMBF)
- the Kompetenznetz “Chronisch entzündliche Darmerkrankungen,”
- the Deutsche Forschungsgemeinschaft (DFG) (to F.R.)
Additional Supporting Information may be found in the online version of this article.
|IBD_21854_sm_SuppFig1.jpg||306K||Supplementary Figure 1: Receiver operating characteristics (ROC) for diagnosis and differentiation of Crohn's disease in the gASCA negative population. Crohn's disease (CD) vs. No CD; CD vs. ulcerative colitis (UC); CD vs. Controls. AUC: Area under the curve; gASCA: anti-Saccharomyces cerevisiae antibodies, ACCA: anti-chitobioside carbohydrate IgA antibodies, ALCA: anti-laminaribioside carbohydrate IgG antibodies, AMCA: anti-mannobioside carbohydrate IgG antibodies, Anti-L: anti-laminarin carbohydrate antibody, Anti-C: anti-chitin carbohydrate antibody.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.